
Opinion|Videos|March 29, 2025
Overview of Spesolimab for Management of GPP
Panelists provide an overview of spesolimab, an IL-36R inhibitor now FDA-approved for treating GPP, discussing the efficacy and safety data from the EFFISAYIL-1 trial (intravenous [IV] formulation) and the EFFISAYIL-2 trial (subcutaneous [SQ] formulation).
Advertisement
Video content above is prompted by the following:
Episodes in this series

- Spesolimab, an IL-36R inhibitor, is now FDA-approved to treat GPP. Can you give a brief overview of spesolimab and the efficacy and safety evidence we have seen to date.
a. EFFISAYIL-1—IV formulation (Bachelez, 2021)
b. EFFISAYIL-2—SQ formulation (Morita, 2023)
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Rethinking “Type 2”: Inside the 2026 AACE Diabetes Classification Algorithm
2
Diagnostic Pearls and New Therapies in Connective Tissue Disease, With Michelle Min, MD
3
VIASKIN Peanut Patch Efficacy Holds in Kids With Atopic Comorbidities
4
Fezolinetant Shows No CNS Safety Signal in Pooled Analysis of 3100 Women, With Marla Shapiro, CM
5

























































